Medicare Enrolled

Dr. Scott Gold, MD

Neurology · Melbourne, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
1223 GATEWAY DR STE 2G, Melbourne, FL 32901
3214736160
In practice since 2006 (20 years)
NPI: 1578522058 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gold from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gold? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Gold

Dr. Scott Gold is a neurology in Melbourne, FL, with 20 years in practice. Based on federal Medicare data, Dr. Gold performed 456 Medicare services across 306 unique beneficiaries.

Between the years covered by Open Payments, Dr. Gold received a total of $303,034 from 63 pharmaceutical and/or device companies across 1076 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Gold is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ 456 Medicare services$ $303,034 industry payments

Medicare Practice Summary

Medicare Utilization ↗
456
Medicare services
Bottom 47% in FL for neurology
306
Unique beneficiaries
$93
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~23 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Office visit, established patient (30-39 min)356$85$255
Office visit, established patient, complex (40-54 min)85$132$358
Office visit, established patient (20-29 min)15$66$180
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$303,034
Total received (2018-2024)
Avg $43,291/year across 7 years
Top 2% in FL for neurology
63
Companies
1,076
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$284,891 (94.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,872 (3.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$8,271 (2.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,271
2023
$1,114
2022
$25,545
2021
$43,648
2020
$34,304
2019
$80,815
2018
$115,337

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$98,280
Biogen, Inc.
$60,627
EMD Serono, Inc.
$53,074
Genentech USA, Inc.
$42,048
Teva Pharmaceuticals USA, Inc.
$12,972
E.R. Squibb & Sons, L.L.C.
$11,465
Celgene Corporation
$8,115
Genentech, Inc.
$4,430
Novartis Pharmaceuticals Corporation
$3,113
TG Therapeutics, Inc.
$1,937
Avanir Pharmaceuticals, Inc.
$545
Sunovion Pharmaceuticals Inc.
$429
Alexion Pharmaceuticals, Inc.
$414
ABBVIE INC.
$379
Amgen Inc.
$370
UCB, Inc.
$332
Lilly USA, LLC
$297
Supernus Pharmaceuticals, Inc.
$284
AbbVie Inc.
$244
Acorda Therapeutics, Inc
$243
Greenwich Biosciences, Inc.
$177
Biohaven Pharmaceuticals, Inc.
$172
Lundbeck LLC
$169
ACADIA Pharmaceuticals Inc
$161
IDORSIA PHARMACEUTICALS US INC
$150
Allergan, Inc.
$140
SANOFI-AVENTIS U.S. LLC
$128
Adamas Pharmaceuticals, Inc.
$123
Eisai Inc.
$123
Bayer HealthCare Pharmaceuticals Inc.
$120
Kyowa Kirin, Inc.
$114
US WorldMeds, LLC
$112
Janssen Pharmaceuticals, Inc
$112
Takeda Pharmaceuticals U.S.A., Inc.
$107
Otsuka America Pharmaceutical, Inc.
$106
Allergan Inc.
$106
TG THERAPEUTICS, INC.
$105
EISAI INC.
$95
SK Life Science, Inc.
$86
Mallinckrodt Enterprises LLC
$83
Grifols USA, LLC
$82
Neurocrine Biosciences, Inc.
$70
Neurelis, Inc.
$66
Horizon Therapeutics plc
$63
Mallinckrodt LLC
$63
GE HEALTHCARE
$59
Ipsen Biopharmaceuticals, Inc
$59
Mallinckrodt Hospital Products Inc.
$54
AbbVie, Inc.
$48
PFIZER INC.
$46
PORTOLA PHARMACEUTICALS, INC.
$44
LivaNova USA, Inc.
$41
Almatica Pharma LLC
$39
Assertio Therapeutics, Inc.
$31
Amneal Pharmaceuticals LLC
$31
BANNER LIFE SCIENCES, LLC
$30
CATALYST PHARMACEUTICALS, INC.
$23
Alnylam Pharmaceuticals Inc.
$20
Biohaven Pharmaceutical Holding Company Ltd.
$19
Merz North America, Inc.
$18
Exeltis, USA Inc.
$14
MITSUBISHI TANABE PHARMA AMERICA, INC.
$13
BOSTON SCIENTIFIC CORPORATION
$13
Top 3 companies account for 70.0% of total payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · AIMOVIG · AJOVY · AMPYRA · ANDEXXA · APOKYN · APTIOM · AUBAGIO · AUSTEDO · AVONEX · Adempas · Aimovig · BAFIERTAM · BEVYXXA · BOTOX · BOTOX THERAPEUTIC · BRIUMVI · Betaseron · Briviact · COPAXONE · Cambia · DUOPA · DYSPORT · Duopa · Dysport · EMGALITY · Enspryng · Epidiolex · Evrysdi · FIRDAPSE · Fycompa · GAMMAGARD · GENERAL DBS · GILENYA · GOCOVRI · GRALISE · Gamunex-C · HYQVIA · INBRIJA · INGREZZA · KESIMPTA · KYNMOBI · LEMTRADA · LYRICA · MAVENCLAD · MAYZENT · MS DISEASE STATE · Mavenclad · NAMZARIC · NORTHERA · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nourianz · Nuedexta · OCREVUS · ONFI · ONPATTRO · Ocrevus · Ozanimod · PLEGRIDY · PURIFIED CORTROPHIN GEL · Ponvory · QULIPTA · QUVIVIQ · RADICAVA · REXULTI · RYTARY · Rebif · SOLIRIS · SPINRAZA · Soliris · TECFIDERA · TROKENDI XR · TYSABRI · UBRELVY · UPLIZNA · VALTOCO · VNS Therapy · VUMERITY · VYEPTI · Vimpat · XEOMIN · Xadago · ZEPOSIA · ZERIT
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for neurology in FL.

Equivalent to $66,455 per 100 Medicare services performed
Looking for a neurology in Melbourne?
Compare neurologys in the Melbourne area by procedure volume, costs, and industry payment transparency.
Browse neurologys nearby

Geographic Context

Neurologys within 10 mi
30
Per 100K population
4.8
County median income
$75,817
Nearest hospital
HOLMES REGIONAL MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Gold is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 2%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Gold experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Gold performed 356 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gold receive payments from pharmaceutical companies?
Yes. Dr. Gold received a total of $303,034 from 63 companies across 1,076 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gold's costs compare to other neurologys in Melbourne?
Dr. Gold's average Medicare payment per service is $93. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gold) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →